Kingsview Wealth Management’s Zevra Therapeutics ZVRA Stock Holding History

Kingsview Wealth Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-12,120	Closed	-$113K	–	1533
2026 Q1	$113K	Hold	12,120	–	–	﹤0.01%	1291
2025 Q4	$109K	Hold	12,120	–	–	﹤0.01%	1210
2025 Q3	$115K	Hold	12,120	–	–	﹤0.01%	1171
2025 Q2	$107K	Hold	12,120	–	–	﹤0.01%	1139
2025 Q1	$90.8K	Hold	12,120	–	–	﹤0.01%	1066
2024 Q4	$101K	Hold	12,120	–	–	﹤0.01%	1080
2024 Q3	$84.1K	Hold	12,120	–	–	﹤0.01%	1072
2024 Q2	$59.4K	Hold	12,120	–	–	﹤0.01%	1024
2024 Q1	$70.3K	Hold	12,120	–	–	﹤0.01%	1000
2023 Q4	$79.4K	Hold	12,120	–	–	﹤0.01%	932
2023 Q3	$58.4K	Hold	12,120	–	–	﹤0.01%	922
2023 Q2	$61.8K	Hold	12,120	–	–	﹤0.01%	890
2023 Q1	$66.7K	Hold	12,120	–	–	﹤0.01%	864
2022 Q4	$55.6K	Hold	12,120	–	–	﹤0.01%	826
2022 Q3	$76K	Hold	12,120	–	–	﹤0.01%	798
2022 Q2	$54K	Hold	12,120	–	–	﹤0.01%	800
2022 Q1	$61K	Sell	12,120 -190	-2%	-$1.21K	﹤0.01%	843
2021 Q4	$107K	Hold	12,310	–	–	﹤0.01%	887
2021 Q3	$115K	Hold	12,310	–	–	0.01%	817
2021 Q2	$164K	Hold	12,310	–	–	0.01%	836
2021 Q1	$117K	Buy	+12,310	New	+$107K	0.01%	791

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Kingsview Wealth Management's ZVRA Position: Q2 2026 in Review

Kingsview Wealth Management sold out of Zevra Therapeutics (ZVRA) in Q2 2026, closing a stake of 12,120 shares — an estimated $113K sold.

Kingsview Wealth Management first reported a position in ZVRA in Q1 2021 and held it in 21 quarters. The position peaked at $164K in Q2 2021. 158 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

Kingsview Wealth Management reported no remaining Zevra Therapeutics position as of Q2 2026 after selling out during the quarter.
Kingsview Wealth Management sold 12,120 Zevra Therapeutics shares in Q2 2026, an estimated $113K.
Kingsview Wealth Management first reported a position in Zevra Therapeutics in Q1 2021 and held it in 21 quarters.
Kingsview Wealth Management's Zevra Therapeutics position peaked at $164K in Q2 2021.
158 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Kingsview Wealth Management's 13F filing for Q2 2026, filed 19 Aug 2026.